Published in Br J Haematol on February 24, 2012
Differential contribution of FXa and thrombin to vascular inflammation in a mouse model of sickle cell disease. Blood (2014) 1.53
Interplay between coagulation and vascular inflammation in sickle cell disease. Br J Haematol (2013) 1.12
Tissue factor promotes activation of coagulation and inflammation in a mouse model of sickle cell disease. Blood (2012) 0.93
Role of the hemostatic system on sickle cell disease pathophysiology and potential therapeutics. Hematol Oncol Clin North Am (2014) 0.84
Coagulation activation in children with sickle cell disease is associated with cerebral small vessel vasculopathy. PLoS One (2013) 0.84
Endothelial activation by platelets from sickle cell anemia patients. PLoS One (2014) 0.83
Excess of heme induces tissue factor-dependent activation of coagulation in mice. Haematologica (2015) 0.82
Elevated hypercoagulability markers in hemoglobin SC disease. Haematologica (2015) 0.80
Coagulation abnormalities of sickle cell disease: Relationship with clinical outcomes and the effect of disease modifying therapies. Blood Rev (2015) 0.80
Coagulation activation in sickle cell trait: an exploratory study. Br J Haematol (2015) 0.80
Proteomic and biomarker studies and neurological complications of pediatric sickle cell disease. Proteomics Clin Appl (2014) 0.75
Emerging point-of-care technologies for sickle cell disease screening and monitoring. Expert Rev Med Devices (2016) 0.75
Thrombin-independent contribution of tissue factor to inflammation and cardiac hypertrophy in a mouse model of sickle cell disease. Blood (2016) 0.75
Sickle cell disease biochip: a functional red blood cell adhesion assay for monitoring sickle cell disease. Transl Res (2016) 0.75
Biomarkers and recent advances in the management and therapy of sickle cell disease. F1000Res (2015) 0.75
Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet (2011) 7.30
Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood (1998) 6.72
Sickle blood contains tissue factor-positive microparticles derived from endothelial cells and monocytes. Blood (2003) 3.04
Role of tissue factor in hemostasis, thrombosis, and vascular development. Arterioscler Thromb Vasc Biol (2004) 3.03
Thrombogenesis in sickle cell disease. J Lab Clin Med (2001) 2.75
Primary role for adherent leukocytes in sickle cell vascular occlusion: a new paradigm. Proc Natl Acad Sci U S A (2002) 2.72
How I use hydroxyurea to treat young patients with sickle cell anemia. Blood (2010) 2.68
Hypoxia/reoxygenation causes inflammatory response in transgenic sickle mice but not in normal mice. J Clin Invest (2000) 2.47
Hypoxaemia in sickle cell disease: biomarker modulation and relevance to pathophysiology. Lancet (2003) 2.15
Reconstructing sickle cell disease: a data-based analysis of the "hyperhemolysis paradigm" for pulmonary hypertension from the perspective of evidence-based medicine. Am J Hematol (2011) 2.13
Activated monocytes in sickle cell disease: potential role in the activation of vascular endothelium and vaso-occlusion. Blood (2000) 2.10
Biologically active CD40 ligand is elevated in sickle cell anemia: potential role for platelet-mediated inflammation. Arterioscler Thromb Vasc Biol (2006) 2.06
Vasculopathy in sickle cell disease: Biology, pathophysiology, genetics, translational medicine, and new research directions. Am J Hematol (2009) 2.05
Antiphospholipid antibodies, proteins C and S, and coagulation changes in sickle cell disease. J Lab Clin Med (1999) 1.82
Whole blood tissue factor procoagulant activity is elevated in patients with sickle cell disease. Blood (1998) 1.79
Endothelial cell expression of tissue factor in sickle mice is augmented by hypoxia/reoxygenation and inhibited by lovastatin. Blood (2004) 1.73
Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer. J Thromb Haemost (2008) 1.70
Deep venous thrombosis and pulmonary embolism in hospitalized patients with sickle cell disease. Am J Med (2006) 1.68
Pulmonary artery thrombosis during acute chest syndrome in sickle cell disease. Am J Respir Crit Care Med (2011) 1.66
Tissue factor expression by endothelial cells in sickle cell anemia. J Clin Invest (1998) 1.58
Cell biology of tissue factor, the principal initiator of blood coagulation. Thromb Res (1996) 1.52
Circulating erythrocyte-derived microparticles are associated with coagulation activation in sickle cell disease. Haematologica (2009) 1.46
Beta-thalassaemia and sickle cell anaemia as paradigms of hypercoagulability. Br J Haematol (2007) 1.45
Increased microparticle tissue factor activity in cancer patients with Venous Thromboembolism. Thromb Res (2009) 1.43
Thrombophilia in sickle cell disease: the red cell connection. Blood (2001) 1.39
Pulmonary thrombotic arteriopathy in patients with sickle cell disease. Arch Pathol Lab Med (2001) 1.31
Pathophysiology of stroke in sickle cell disease. Microcirculation (2004) 1.28
Pre-analytical and analytical variables affecting the measurement of plasma-derived microparticle tissue factor activity. Thromb Res (2011) 1.25
Sickle cell acute chest syndrome: pathogenesis and rationale for treatment. Blood (1999) 1.25
Association of coagulation activation with clinical complications in sickle cell disease. PLoS One (2012) 1.17
Short survival of phosphatidylserine-exposing red blood cells in murine sickle cell anemia. Blood (2001) 1.17
Tissue factor and its measurement in whole blood, plasma, and microparticles. Semin Thromb Hemost (2010) 1.17
Heme induces endothelial tissue factor expression: potential role in hemostatic activation in patients with hemolytic anemia. J Thromb Haemost (2008) 1.14
Phosphatidylserine externalization in sickle red blood cells: associations with cell age, density, and hemoglobin F. Blood (2003) 1.02
Increased levels of the inflammatory biomarker C-reactive protein at baseline are associated with childhood sickle cell vasocclusive crises. Br J Haematol (2009) 1.00
Tissue factor in patients with acute coronary syndromes: expression in platelets, leukocytes, and platelet-leukocyte aggregates. Arterioscler Thromb Vasc Biol (2008) 0.97
Plasma levels of tissue factor and soluble E-selectin in sickle cell disease: relationship to genotype and to inflammation. Blood Coagul Fibrinolysis (2005) 0.96
Hemostatic alterations in sickle cell disease: relationships to disease pathophysiology. Pediatr Pathol Mol Med (2003) 0.94
Soluble P-selectin and vascular endothelial growth factor in steady state sickle cell disease: relationship to genotype. J Thromb Thrombolysis (2007) 0.88
Tissue factor activity of blood mononuclear cells is increased after total knee arthroplasty. Thromb Haemost (2009) 0.86
Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol (2013) 5.56
Sickle blood contains tissue factor-positive microparticles derived from endothelial cells and monocytes. Blood (2003) 3.04
Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis. Arterioscler Thromb Vasc Biol (2007) 2.70
Definitions of the phenotypic manifestations of sickle cell disease. Am J Hematol (2010) 2.55
Comparison of characteristics from White- and Black-Americans with venous thromboembolism: a cross-sectional study. Am J Hematol (2010) 2.26
Hypoxaemia in sickle cell disease: biomarker modulation and relevance to pathophysiology. Lancet (2003) 2.15
Sickle cell trait and the risk of venous thromboembolism among blacks. Blood (2007) 1.95
Induction of microparticle- and cell-associated intravascular tissue factor in human endotoxemia. Blood (2004) 1.82
Red blood cell alloimmunization in sickle cell disease: prevalence in 2010. Transfusion (2012) 1.80
Hypercoagulability in sickle cell disease: new approaches to an old problem. Hematology Am Soc Hematol Educ Program (2007) 1.65
D-dimer antigen: current concepts and future prospects. Blood (2008) 1.59
Andrographolide attenuates inflammation by inhibition of NF-kappa B activation through covalent modification of reduced cysteine 62 of p50. J Immunol (2004) 1.58
Differential contribution of FXa and thrombin to vascular inflammation in a mouse model of sickle cell disease. Blood (2014) 1.53
Effects of hyperglycemia and hyperinsulinemia on circulating tissue factor procoagulant activity and platelet CD40 ligand. Diabetes (2006) 1.50
PF4/heparin-antibody complex induces monocyte tissue factor expression and release of tissue factor positive microparticles by activation of FcγRI. Blood (2012) 1.48
Platelet microparticles are heterogeneous and highly dependent on the activation mechanism: studies using a new digital flow cytometer. Cytometry A (2007) 1.48
Role of erythrocyte phosphatidylserine in sickle red cell-endothelial adhesion. Blood (2002) 1.47
Increased microparticle tissue factor activity in cancer patients with Venous Thromboembolism. Thromb Res (2009) 1.43
Major burn injury is not associated with acute traumatic coagulopathy. J Trauma Acute Care Surg (2013) 1.43
Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients. Blood (2011) 1.43
Circulating tissue factor procoagulant activity and thrombin generation in patients with type 2 diabetes: effects of insulin and glucose. J Clin Endocrinol Metab (2007) 1.33
Clinical trial implementation and recruitment: lessons learned from the early closure of a randomized clinical trial. Contemp Clin Trials (2011) 1.28
Blood coagulation: hemostasis and thrombin regulation. Anesth Analg (2009) 1.24
High prevalence of sickle cell trait in African Americans with ESRD. J Am Soc Nephrol (2010) 1.23
Tumor-derived tissue factor activates coagulation and enhances thrombosis in a mouse xenograft model of human pancreatic cancer. Blood (2012) 1.20
Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, part 2: Treatment. Am J Hematol (2009) 1.18
Association of coagulation activation with clinical complications in sickle cell disease. PLoS One (2012) 1.17
Regulation of platelet myosin light chain (MYL9) by RUNX1: implications for thrombocytopenia and platelet dysfunction in RUNX1 haplodeficiency. Blood (2010) 1.17
Role of procoagulant microparticles in mediating complications and outcome of acute liver injury/acute liver failure. Hepatology (2013) 1.11
Plasma protein profiling: unique and stable features of individuals. Proteomics (2005) 1.11
Hemostatic abnormalities in sickle cell disease. Curr Opin Hematol (2013) 1.08
Effects of tissue factor, thrombomodulin and elevated clotting factor levels on thrombin generation in the calibrated automated thrombogram. Thromb Haemost (2009) 1.07
RUNX1/core binding factor A2 regulates platelet 12-lipoxygenase gene (ALOX12): studies in human RUNX1 haplodeficiency. Blood (2010) 1.03
Platelet and monocyte activation by hyperglycemia and hyperinsulinemia in healthy subjects. Platelets (2006) 1.03
Pediatric analgesic clinical trial designs, measures, and extrapolation: report of an FDA scientific workshop. Pediatrics (2012) 1.03
Microparticles in cardiovascular disease pathophysiology and outcomes. J Am Soc Hypertens (2012) 1.01
Circulating tissue factor procoagulant activity is elevated in stable moderate to severe chronic obstructive pulmonary disease. Thromb Res (2009) 0.98
Centrifugation is a crucial step impacting microparticle measurement. Platelets (2009) 0.98
Circulating microparticle tissue factor, thromboembolism and survival in pancreaticobiliary cancers. Thromb Res (2013) 0.97
Hepatitis C in adults and adolescents with hemophilia: a randomized, controlled trial of interferon alfa-2b and ribavirin. Hepatology (2002) 0.97
Hormonal contraception, sickle cell trait, and risk for venous thromboembolism among African American women. Am J Obstet Gynecol (2009) 0.96
NF-kappaB transcription factor p50 critically regulates tissue factor in deep vein thrombosis. J Biol Chem (2008) 0.95
Managing PAD with multiple platelet inhibitors: the effect of combination therapy on bleeding time. J Vasc Surg (2003) 0.94
Measurement of bleeding severity: a critical review. Transfusion (2004) 0.93
Tissue factor promotes activation of coagulation and inflammation in a mouse model of sickle cell disease. Blood (2012) 0.93
Novel oral anticoagulants: implications in the perioperative setting. Anesthesiology (2010) 0.93
Thrombin generation and whole blood viscoelastic assays in the management of hemophilia: current state of art and future perspectives. Blood (2013) 0.93
Tapered oral dexamethasone for the acute chest syndrome of sickle cell disease. Br J Haematol (2011) 0.92
Cytokine production by CD4+ T cells specific for coagulation factor VIII in healthy subjects and haemophilia A patients. Thromb Haemost (2007) 0.91
Anthracycline treatment of the human monocytic leukemia cell line THP-1 increases phosphatidylserine exposure and tissue factor activity. Thromb Res (2011) 0.91
Inpatient management of sickle cell pain: a 'snapshot' of current practice. Am J Hematol (2012) 0.90
Analysis of individual platelet-derived microparticles, comparing flow cytometry and capillary electrophoresis with laser-induced fluorescence detection. Analyst (2003) 0.90
Microparticles and cancer. Pathophysiol Haemost Thromb (2009) 0.89
Platelet factor 4 enhances generation of activated protein C in vitro and in vivo. Blood (2003) 0.89
Red cell aplasia and autoimmune hemolytic anemia following immunosuppression with alemtuzumab, mycophenolate, and daclizumab in pancreas transplant recipients. Haematologica (2007) 0.89
Acquired hemophilia in malignancy. Thromb Res (2012) 0.88
A pilot study of eptifibatide for treatment of acute pain episodes in sickle cell disease. Thromb Res (2013) 0.88
Factor VIIa and tissue factor procoagulant activity in diabetes mellitus after acute ischemic stroke: impact of hyperglycemia. Thromb Haemost (2007) 0.87
Circulating levels of tissue factor microparticle procoagulant activity are reduced with antiretroviral therapy and are associated with persistent inflammation and coagulation activation among HIV-positive patients. J Acquir Immune Defic Syndr (2013) 0.87
Postoperative coagulopathy in a pediatric patient after exposure to bovine topical thrombin. Ann Thorac Surg (2007) 0.87
Effects of hyperglycemia and hyperinsulinemia on the tissue factor pathway of blood coagulation. Curr Diab Rep (2007) 0.87
PROMIS(®) pediatric self-report scales distinguish subgroups of children within and across six common pediatric chronic health conditions. Qual Life Res (2015) 0.87
Hematologic changes in sepsis and their therapeutic implications. Semin Respir Crit Care Med (2004) 0.86
Platelet protein kinase C-theta deficiency with human RUNX1 mutation: PRKCQ is a transcriptional target of RUNX1. Arterioscler Thromb Vasc Biol (2011) 0.86
Elevated whole-blood tissue factor procoagulant activity as a marker of restenosis after percutaneous transluminal coronary angioplasty and stent implantation. Circulation (2003) 0.86
Association of soluble fms-like tyrosine kinase-1 with pulmonary hypertension and haemolysis in sickle cell disease. Br J Haematol (2011) 0.85
Eicosanoids in sickle cell disease: potential relevance of neutrophil leukotriene B4 to disease pathophysiology. J Lab Clin Med (2002) 0.85
Mice with heterozygous deficiency of lipoic acid synthase have an increased sensitivity to lipopolysaccharide-induced tissue injury. J Leukoc Biol (2008) 0.84
Lupus anticoagulant associated with transient severe factor X deficiency: a report of two patients presenting with major bleeding complications. Br J Haematol (2003) 0.84
Activated recombinant factor VII in cardiac surgery. Curr Opin Anaesthesiol (2005) 0.84
Venous thromboembolism in multiple myeloma: current perspectives in pathogenesis. Eur J Cancer (2010) 0.84
Blood utilization in patients with burn injury and association with clinical outcomes (CME). Transfusion (2012) 0.83
Role of Galphaq and phospholipase C-beta2 in human platelets activation by thrombin receptors PAR1 and PAR4: studies in human platelets deficient in Galphaq and phospholipase C-beta2. Br J Haematol (2003) 0.83
Venous thrombosis in blacks. Circulation (2012) 0.83
Clinical and laboratory management of the prothrombin G20210A mutation. Arch Pathol Lab Med (2002) 0.83
Whole-blood tissue factor procoagulant activity is elevated in type 1 diabetes: effects of hyperglycemia and hyperinsulinemia. Diabetes Care (2012) 0.82
Sickle trait in African-American hemodialysis patients and higher erythropoiesis-stimulating agent dose. J Am Soc Nephrol (2014) 0.80
Standardized reporting of bleeding complications for clinical investigations in acute coronary syndromes: a proposal from the academic bleeding consensus (ABC) multidisciplinary working group. Am Heart J (2009) 0.80
Role of the geneticist in testing and counseling for inherited thrombophilia. Genet Med (2003) 0.79
Response of complex immune-mediated thrombocytopenia to romiplostim in the setting of allogeneic stem cell transplantation for chronic myelogenous leukemia. Eur J Haematol (2012) 0.79
Changes in bleeding patterns in von Willebrand disease after institution of long-term replacement therapy: results from the von Willebrand Disease Prophylaxis Network. Blood Coagul Fibrinolysis (2015) 0.79
The White platelet syndrome: a new autosomal dominant platelet disorder. Platelets (2004) 0.79
Studies on the mechanism of action of the aptamer BAX499, an inhibitor of tissue factor pathway inhibitor. Thromb Res (2012) 0.79
Differential effects of somatostatin on circulating tissue factor procoagulant activity and protein. Am J Physiol Endocrinol Metab (2007) 0.78
Phenotypes of allo- and autoimmune antibody responses to FVIII characterized by surface plasmon resonance. PLoS One (2013) 0.78
A review of current methods for assessing hemostasis in vivo and introduction to a potential alternative approach. Thromb Res (2012) 0.78
De novo synthesis of a narrow size distribution low-molecular-weight heparin. Glycobiology (2014) 0.78
P2Y(12) antagonists as antiplatelet agents - Recent developments. Curr Opin Drug Discov Devel (2010) 0.78
Recombinant FVIIa for intractable hemorrhage: more questions than answers. Transfusion (2003) 0.78
Variant hemoglobin phenotypes may account for differential erythropoiesis-stimulating agent dosing in African-American hemodialysis patients. Kidney Int (2011) 0.78
Medical management of venous thromboembolism: what the interventional radiologist needs to know. Semin Intervent Radiol (2012) 0.78
Alternative splice variants of phospholipase C-beta2 are expressed in platelets: effect on Galphaq-dependent activation and localization. Platelets (2007) 0.78
Characteristics of abdominal vein thrombosis in children and adults. Thromb Haemost (2013) 0.77
Microparticles in thrombosis and hemostasis. Semin Thromb Hemost (2010) 0.77
Phorbol 12-myristate 13-acetate (PMA) responsive sequence in Galphaq promoter during megakaryocytic differentiation. Regulation by EGR-1 and MAP kinase pathway. Thromb Haemost (2008) 0.77